Abstract
Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 277-285 |
| Number of pages | 9 |
| Journal | Oral Diseases |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 2008 |
| Externally published | Yes |
Keywords
- Biology
- Bisphosphonates
- Bone marrow
- Jaw
- Osteonecrosis
ASJC Scopus subject areas
- Otorhinolaryngology
- General Dentistry
Fingerprint
Dive into the research topics of 'Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS